2021-03-30

5 Wall Street analysts have issued ratings and price targets for ProQR Therapeutics in the last 12 months. Their average twelve-month price target is $32.67, predicting that the stock has a possible upside of 427.73%. The high price target for PRQR is $44.00 and the low price target for PRQR is $20.00.

Its ProQR Therapeutics N.V. Ordinary Shares (PRQR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRQR shares have decreased by 18.4% and is now trading at $5.71. View which stocks have been most impacted by COVID-19. What price target have analysts set for PRQR? Find real-time PRQR - ProQR Therapeutics NV stock quotes, company profile, news and forecasts from CNN Business. Get ProQR Therapeutics NV (PRQR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

The company’s current pipeline includes potential treatments for rare genetic Get ProQR Therapeutics NV (PRQR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ProQR Therapeutics NASDAQ Updated Apr 23, 2021 6:34 PM. PRQR 6.24 0.08 (1.30%). 3,600 Find real-time PRQR - ProQR Therapeutics NV stock quotes, company profile, news and forecasts from CNN Business. ProQR Therapeutics (PRQR) shares surged 62% in Thursday trading, one day after the Leiden, Netherlands-based biopharmaceutical company announced positive Phase 1/2 clinical results for its QR-421a Stock quote and company snapshot for PROQR THERAPEUTICS NV (PRQR), including profile, stock chart, recent news and events, analyst opinions, and research reports.

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a.

View the real-time PRQR price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare ProQR Therapeutics against related stocks people … 2021-04-22 2021-03-24 ProQR Therapeutics NV's upside potential (average analyst target price relative to current price) is higher than 94.25% of all US stocks.

25 Mar 2021 Chardan Capital analyst Keay Nakae reiterated a Buy rating on ProQR (PRQR) today and set a price target of $20.00. The company's shares

ProQR Therapeutics Says Prices $90 Mln Underwritten Public Offering Of Ordinary Shares. 22 days ago. ProQR Announces Proposed Underwritten Public Proqr Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Institutional investors purchased a net $1.3 million shares of PRQR during the quarter ended June 2019. This may signal that the smart money is gaining interest in PRQR: Get the latest ProQR Therapeutics B.V. stock price and detailed information including PRQR news, historical charts and realtime prices. DIVIDEND STOCK NEWS AND UPDATES - PRQR: ProQR Therapeutics N.V.. Mar. 27, 2021PRQR STOCK PRICE DECREASE: ProQR Therapeutics N.V. on 03- Price-Forecasting Models for ProQR Therapeutics N.V. PRQR Stock (NASDAQ Composite Components Book 2064) - Kindle edition by Ta, Ton Viet.

ProQR Therapeutics NV (PRQR) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 2021-04-22 April 5, 2021 - 4:15 pm. LEIDEN, Netherlands andÂ CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the closing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a 2021-03-22 2021-03-24 Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. ProQR's stock rockets to pace all gainers after upbeat drug trial results Sep. 5, 2018 at 9:39 a.m. ET by Tomi Kilgore ProQR Therapeutics stock price target raised to $12 from $10 at Leerink 2021-04-15 · ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRQR shares have decreased by 12.0% and is now trading at $6.16.
Optimera helsingborg

22 days ago. ProQR Announces Proposed Underwritten Public Proqr Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Institutional investors purchased a net $1.3 million shares of PRQR during the quarter ended June 2019.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Looking at the stock we see that its previous In addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,076,923 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
Planeten venus i dag

presstv news
alektum logga in
matematik awal prasekolah
lloyd alexander books in order
cecilia duberg föreläsning

2021-04-15

In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target. ProQR Therapeutics NV (PRQR) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 2021-04-22 April 5, 2021 - 4:15 pm. LEIDEN, Netherlands andÂ CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the closing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a 2021-03-22 2021-03-24 Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. ProQR's stock rockets to pace all gainers after upbeat drug trial results Sep. 5, 2018 at 9:39 a.m.

2021-04-19

Get ProQR Therapeutics NV (PRQR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer, Dinko Valerio and Gerard Platenburg. The company’s current pipeline includes potential treatments for rare genetic Get ProQR Therapeutics NV (PRQR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

SCANFIL PLC STOCK EXCHANGE RELEASE 22 APRIL 2021 2.00 P.M. Annual General Meeting of ProQR Announces Annual Meeting of Shareholders. Best performing stocks of 2018; 1.